Showing results (81-90 of 6,269) with videos related to

Sort By:
Pageof 627
Diabetes, Obesity & Metabolism|August 1, 2019
Prevention of type 2 diabetes in prediabetic patients by using functional olive oil enriched in oleanolic acid: The PREDIABOLE study, a randomized controlled trialJosé M Santos-Lozano, Mirela Rada, José Lapetra, et al.
Diabetes, Obesity & Metabolism|August 1, 2019
Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trialFrancesco Giorgino, Maria Yu, Axel Haupt, et al.
Diabetes, Obesity & Metabolism|August 1, 2019
A novel specific peroxisome proliferator-activated receptor γ (PPARγ) modulator YR4-42 ameliorates hyperglycaemia and dyslipidaemia and hepatic steatosis in diet-induced obese miceYi Huan, Xuan Pan, Jun Peng, et al.
Diabetes, Obesity & Metabolism|April 21, 2024
Cardiorenal outcomes and mortality after sodium-glucose cotransporter-2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention historyJin Hwa Kim, Young Sang Lyu, BongSeong Kim, et al.
Diabetes, Obesity & Metabolism|April 22, 2024
Biotransformation and disposition characteristics of HSK7653, a novel long-acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetesYi-Cong Bian, Jian Meng, Tao Hu, et al.
Diabetes, Obesity & Metabolism|April 15, 2024
Combination of retagliptin and henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, active-controlled, phase 3 trialYao Wang, Chengxia Jiang, Xiaolin Dong, et al.
Diabetes, Obesity & Metabolism|April 15, 2024
Association of single-point insulin sensitivity estimator index (SPISE) with future cardiovascular outcomes in patients with type 2 diabetesSimin Deng, Xinqun Hu, Xiangyu Zhang
Diabetes, Obesity & Metabolism|April 15, 2024
Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, AustraliaJuliana de Oliveira Costa, Jialing Lin, Tamara Y Milder, et al.
Diabetes, Obesity & Metabolism|August 16, 2014
Weight changes in obese adults 6-months after discontinuation of double-blind zonisamide or placebo treatmentJ H Shin, K M Gadde, T Østbye, et al.
Diabetes, Obesity & Metabolism|December 31, 2013
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndromeA M van den Hoek, J W A van der Hoorn, A C Maas, et al.
Pageof 627